ClinicalTrials.gg
CompletedNCT04911062Updated Jun 12, 2023

HTX-011 in Spinal Surgery

A Phase 2 interventional study of Bupivacaine HCI without epinephrine and HTX-011 in Post-Operative Pain and Lumbar Laminectomy, sponsored by Heron Therapeutics. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-12.

Sponsored by Heron Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2022, 4 years 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jun 2023.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
308th of 364
32 · median 70
Started
2022
with 24 others
Phase 2
43 of 364
4 open now
Registered
229th of 364
by date
Lead sponsor
17 of 364
Heron Therapeutics

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 308th largest by enrollment, is one of 25 that started in 2022, is one of 43 in phase 2, and was the 229th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter study in subjects undergoing an open lumbar decompression surgery.

03

Conditions studied

  • Post-Operative Pain
  • Lumbar Laminectomy

Browse trials for

Keywords

  • postoperative pain
  • local anesthetic
  • lumbar laminectomy
  • lumbar decompression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is scheduled to undergo an open 1-3 level lumbar decompression surgery with or without fixation under general anesthesia.
  • Females are eligible only if not pregnant, not lactating, not planning to become pregnant during the study.

Exclusion criteria

Exclusion Criteria:

  • Has a of a known or suspected history of or idiosyncratic reaction to required study medications.
  • Has a history of severe allergic reaction due to aspirin or other NSAIDs, or known history of severe gastrointestinal adverse reactions associated with NSAID use.
  • Has functioning intrathecal drug pump or spinal cord stimulator.
  • Opioid use for most days within the last 3 months.
  • Has initiated treatment with selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), gabapentin, pregabalin, or duloxetine within 1 month prior to the scheduled surgery.
  • Received an product or device in a clinical trial within 30 days or within 5 elimination half-lives.
  • Has a history of clinically significant cardiac abnormality, coronary artery bypass graft surgery within 12 months, or suspected coagulopathy or uncontrolled anticoagulation.
  • Has impaired balance and is at risk of falling.
  • Is currently undergoing treatment for , , or .
  • Has undergone 3 or more surgeries within 12 months.
  • Has a known history of glucose-6-phosphate dehydrogenase deficiency.
  • Has History of liver cirrhosis, having an >3 × the (ULN), or having an alanine aminotransferase >3 × ULN.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Cohort 1: Bupivacaine HCl

    Bupivacaine HCl without epinephrine, via injection into the surgical site.

    Drug: Bupivacaine HCI without epinephrine

  • Experimental
    Cohort 2: HTX-011

    HTX-011 (bupivacaine/meloxicam) via application into the surgical site.

    Drug: HTX-011 · Device: Luer Lock Applicator

  • Experimental
    Cohort 3: HTX-011

    HTX-011 (bupivacaine/meloxicam) via application into the surgical site.

    Drug: HTX-011 · Device: Luer Lock Applicator

Interventions

  • DrugBupivacaine HCI without epinephrine

    100 mg administered via injection into the surgical site.

  • DrugHTX-011

    Drug pages: Bupivacaine · Meloxicam

    HTX-011 (bupivacaine/meloxicam) dose up to 200 mg/6 mg administered via application into the surgical site.

  • DeviceLuer Lock Applicator

    Applicator for instillation.

06

What researchers measure

Primary outcomes

  1. Incidence of Serious Adverse Events

    Time frame: From the time the subject signs the ICF through the Day 29 Visit

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Baseline through 120 hours

  2. Time of occurrence of maximum concentration (Tmax)

    Time frame: Baseline through 120 hours

  3. Area under the concentration-time curve from Time 0 to the time of last quantitative concentration (AUClast)

    Time frame: Baseline through 120 hours

  4. Area under the concentration-time curve from Time 0 extrapolated to infinity (AUCinf)

    Time frame: Baseline through 120 hours

  5. Apparent terminal half-life (t½)

    Time frame: Baseline through 120 hours

07

Study locations

12 sites
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • Lotus Clinical Research, LLC
    Pasadena, California 91105, United States
  • Kansas Spine and Specialty Hospital
    Wichita, Kansas 67226, United States
  • Spine Institute of Louisiana
    Shreveport, Louisiana 71101, United States
  • Overlook Medical Center
    Summit, New Jersey 07901, United States
  • M3 Emerging Medical Research, LLC
    Durham, North Carolina 27704, United States
  • The Ohio State University Wexner Medical Center - University Hospital
    Columbus, Ohio 43210, United States
  • Austin Neurosurgeons
    Austin, Texas 78746, United States
  • First Surgical Hospital
    Bellaire, Texas 77401, United States
  • Houston Heights Hospital
    Houston, Texas 77008, United States
  • South Texas Spine & Surgical Center
    San Antonio, Texas 78258, United States
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jul 2022, 3 months.

Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 3 months is below that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2021
First posted
Jun 2, 2021
StartActual
Apr 7, 2022
Primary completionActual
Jul 29, 2022
CompletionActual
Aug 26, 2022
Results delay requested
Jun 5, 2023
Last update
Jun 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04911062
Lead sponsor
Heron Therapeutics
Responsible party
Sponsor
First posted
Jun 2, 2021
Start date
Apr 7, 2022
Primary completion
Jul 29, 2022
Completion
Aug 26, 2022
Last update
Jun 12, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Meloxicam

Start the discussion